PolyPid Ltd. (PYPD)
| Market Cap | 84.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -34.17M |
| Shares Out | 19.08M |
| EPS (ttm) | -2.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,701 |
| Open | 4.530 |
| Previous Close | 4.580 |
| Day's Range | 4.400 - 4.530 |
| 52-Week Range | 2.440 - 5.120 |
| Beta | 1.46 |
| Analysts | Strong Buy |
| Price Target | 12.25 (+175.28%) |
| Earnings Date | May 13, 2026 |
About PYPD
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral ca... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for PYPD stock is "Strong Buy." The 12-month stock price target is $12.25, which is an increase of 175.28% from the latest price.
News
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PET...
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision site Analysis demonstrates D-PLEX₁₀₀ prolonged de...
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 202...
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application
FDA Grants $4. 3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations
PolyPid Transcript: The Citizens Life Sciences Conference 2026
D-PLEX₁₀₀ is nearing NDA submission, with robust Phase 3 data showing significant reductions in surgical site infections and related complications. Regulatory alignment and market preparation are strong, with plans for label expansion and a focus on strategic partnerships.
PolyPid Announces Participation in Upcoming Investor Conferences
PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by ele...
PolyPid Earnings Call Transcript: Q4 2025
SHIELD II Phase III trial success and positive FDA feedback position D-PLEX100 for a rolling NDA submission in Q1 2026, with advanced U.S. partnership talks and a strengthened balance sheet. The company is transitioning to commercialization, introducing the Kynatrix platform, and expects cash to last into H2 2026.
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
The Company is in Advanced Stage s of Commercial U.S. Partner ship Discussions for D-PLEX₁₀₀
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...
PolyPid Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
A novel drug delivery platform is advancing toward FDA approval, with D-PLEX 100 showing strong phase 3 results in reducing surgical site infections. Commercialization plans include a U.S. partnership, and financial resources are sufficient through 2026.
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
Appointment Enhances PolyPid's Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application Submission Appointment Enhances PolyPid's Strategic, Commercial and Transactio...
PolyPid Transcript: KOL Event
D-PLEX100, a novel local antibiotic delivery system, demonstrated a 60% reduction in surgical site infections and strong safety in a large phase 3 trial. Regulatory submission is planned for early 2026, with high anticipated adoption among surgeons and hospitals due to robust efficacy, safety, and economic benefits.
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission
PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...
PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025
Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX₁₀₀ Inter...
PolyPid Earnings Call Transcript: Q3 2025
Q3 2025 saw regulatory, commercial, and manufacturing progress for D-PLEX100, with a pre-NDA FDA meeting set for December and NDA submission on track for early 2026. Financial discipline was maintained, net loss improved, and market access studies confirmed strong U.S. demand.
PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026
PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
PETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company focused on improving surgical outcomes, today announced...
PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025
PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...
PolyPid Transcript: Lytham Partners Fall 2025 Investor Conference
D-PLEX100 demonstrated strong Phase 3 results in reducing surgical site infections, with NDA submission planned for Q1 next year. The product targets a large market, offers significant hospital cost savings, and has attracted strong commercial interest. Cash runway extends into 2026.
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world's leading surgical conferences The Company will present the reported topline results from its...
PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference
PETACH TIKVA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced t...
PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀
PETACH TIKVA, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd.
PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced t...
PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced t...
PolyPid Earnings Call Transcript: Q2 2025
Q2 2025 saw pivotal phase III results for D-PLEX 100, showing strong efficacy and safety in reducing surgical site infections, driving regulatory and commercial momentum. Financials improved with a strengthened cash position and ongoing partnership discussions in the U.S. and Europe.